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Abstract: Thrombosis is a common complication in patients with cancer and it is estimated that about 20% of patients 
with cancer experience venous thromboembolism (VTE). This complication is associated with high rate of morbidity and 
mortality and is sometimes the first manifestation of an occult cancer. The risk profiles and markers involved in cancer-
associated thrombosis share similarities with inflammation-induced atherosclerosis and thrombosis. The type of cancer, 
chemotherapy, surgery, central venous catheters, pre-chemotherapy platelet and leukocyte count are associated with high 
risk of VTE in cancer patients. Landmark studies demonstrated that effective prophylaxis and treatment of VTE reduced 
morbidity and increased survival. Low-molecular-weight heparin (LMWH) is preferred as an effective and safe means for 
prophylaxis and treatment of VTE. It has largely replaced unfractionated heparin and vitamin K antagonists. The advan-
tages of LMWH include increased survival and quality of life, decreased rate of VTE, low incidence of thrombocytopenia. 
New guidelines for prophylaxis and treatment are now available and prophylaxis is recommended in hospitalized cancer 
patients and patients undergoing major surgery. Treatment with LMWH should be considered as the first line of therapy 
for established VTE and to prevent recurrent thrombosis in patients with cancer. 
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INTRODUCTION 
  Thrombosis,  a  well-recognized  complication  of  cancer, 
may be the first manifestation of malignancy and is associ-
ated with a high rate of morbidity and mortality [1-4]. This 
association  was  first  described  by  Armand  Trousseau  in 
1865  and  the  condition  still  often  called  Trousseau’s  
syndrome [5-7].  
  The clinical manifestations of thrombosis in cancer vary 
from  venous  thromboembolism  (VTE)  to  disseminated  in-
travascular  coagulation,  which  is  more  commonly  seen  in 
hematological  malignancies  [8].  Venous  thromboembolism 
in patients with cancer may present as a vast range of clini-
cally  significant  thrombotic  complications  including  deep 
vein thrombosis, pulmonary embolism, arterial  thrombosis, 
nonbacterial  thrombotic  endocarditis,  superficial  thrombo-
phlebitis, catheter-related thrombosis and hepatic venoocclu-
sive disease [9-11]. 
  Certain  malignancies,  particularly  mucin-secreting  ade-
nocarcinomas of the ovary, pancreas, stomach, brain tumors 
and hematological malignancies, are associated with a higher 
risk of VTE [12-16]. Some conditions are well-known risk 
factors for increased risk of thrombosis in patients with can-
cer. Chemotherapy is one of the most important risk factors 
for  increased  risk  of  VTE  [10-12].  The  strongest  clinical 
relationship  between  chemotherapy  and  thrombosis  was 
found in patients with breast cancer receiving chemotherapy 
[10, 12-15]. In a study by the Eastern Cooperative Oncology 
Group, VTE was significantly more common in patients with  
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breast  cancer  who  underwent  chemotherapy  and  hormonal 
therapy than in the control group [16]. A high incidence of 
VTE  following  chemotherapy  was  also  reported  in  other 
cancers [17, 18]. Chemotherapy increased the risk of VTE 
and recurrent VTE 6-fold and 2-fold, respectively in patients 
with cancer, and it is estimated that the annual incidence of 
VTE  in cancer patients undergoing chemotherapy is  about 
10.9% [10]. 
  Surgery is estimated to increase the risk of postoperative 
VTE about 2-fold in patients with cancer compared to pa-
tients without cancer who underwent surgery and was asso-
ciated with a 3-fold to 4-fold increase in the likelihood of 
developing  pulmonary  embolism  after  surgery  [19-21].  In 
contrast, some studies did not show an increased risk of VTE 
associated with surgery in patients with cancer [14, 22]. One 
study  that  analyzed  the  effect  of  neurosurgery  on  the  risk  
of  thrombosis  in  patients  with  glioma  revealed  that  these 
patients were 70% more likely to develope VTE compared to 
patients who did not undergo surgery [14]. Other risk factors 
for  thrombosis  in  cancer  are  central  venous  catheters,  
immobilization,  oral  contraceptive  use,  trauma,  previous 
vein  thrombosis,  hormonal  therapy,  pregnancy,  older  age, 
prothrombotic  mutations  such  as  factor  V  leiden  and 
prothrombin  20210A,  elevated  D-dimer  levels,  elevated  
C-reactive  protein,  elevated  soluble  P-selectin,  body  mass  
index  ≥35  kg/m
2,  antiphospholipid  antibody  and  several  
biomarkers  such  as  pre-chemotherapy  platelet  count  over 
350 × 10
3/µL or leukocyte count over 11 × 10
3/µL [14, 22-
26]. 
  Also it is noted that risk factors and markers involved in 
cancer-associated thrombosis, inflammation and atheroscle-
rosis share similarities. Thrombogenic risk factors such as 
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coronary  atherosclerosis  plague.  In  addition,  platelets  can 
release  pro-inflammatory  substances  relevant  to  athero- 
thrombosis. Beside the cardiovascular risk factors including; 
family  history  of  coronary  heart  disease,  smoking,  high  
cholesterol  level,  hypertension,  age  and  diabetic  mellitus 
several  markers  including  fibrinogen  level,  markers  of  
fibrinolytic  systems  and  inflammation  markers  such  as  C-
reactive protein is evaluated as risk factors of cardiovascular 
disease [27, 28]. 
  The  aim  of  this  review  was  to  overview  evidence  on 
pathophysiology,  prophylaxis  and  treatment  of  cancer-
associated thrombosis. 
PATHOPHYSIOLOGY  OF  CANCER-ASSOCIATED 
THROMBOSIS 
  The pathophysiology of thrombosis formation and blood 
coagulation  in  cancer  is  complex  and  reflects  different 
mechanisms that are generally related to the host response to 
cancer. These mechanisms include activation of the coagula-
tion and fibrinolytic systems, acute phase reaction, inflam-
mation,  necrosis  and  cytokine  production  [5,  8,  29,  30].  
Malignant  cells  can  directly  activate  blood  coagulation  
by  producing  tissue  factor,  cancer  procoagulant  activity,  
inflammatory reactions and cytokines [9, 12, 29, 31]. 
  Tissue  factor,  an  important  coagulation  factor  that  has 
been reported in many types of cancers [32], is constitutively 
expressed on solid malignant  cells  and acute myelogenous 
leukemia cells. It has been reported to promote thrombotic 
state [30, 31, 33]. 
  Cancer procoagulant is a 68-kDa cysteine endopeptidase 
that can directly activate coagulation factor X. It is released 
by many tumor cells and its activity promotes thrombosis. It 
is also has been shown that cancer procoagulant can cause 
platelet activation [8, 10, 34, 35]. 
  Malignant cells release various types of cytokines includ-
ing interleukin (IL)-1β, tumor necrosis factor-α and vascular 
endothelial  growth  factor  (VEGF),  which  have  important 
effects  on  coagulation.  These  cytokines  can  induce  tissue 
factor production by vascular endothelial cells, downregulate 
thrombomodulin expression, produce plasminogen activator 
inhibitor-1 and increase endothelial cell adhesion molecule 
expression. This last effect increases the capacity of the ves-
sel wall to attach leukocytes and platelets, promoting local-
ized clotting factor activation and thrombosis formation [8-
10, 29, 36]. Angiogenesis is an important process in patho-
physiology  of  cancer.  VEGF  and  angiopoietins  with  their 
receptors, Flt-1 for VEGF and Tie-2 for angiopoietin,  that 
are the most potent proangiogenic factors are involved in the 
pathogenesis of cancer. Abnormal  levels of VEGF,  angio-
poietins,  IL-6  (an  inflammatory  cytokine)  and  soluble  P  
selectin  and  their  receptors  are  established  in  breast  and 
other cancers that treatment is effective in reduce levels of 
these markers [37-39]. 
  Interactions  between  malignant  and  endothelial  host 
cells,  platelets  and  leukocytes  are  another  mechanism  by 
which  tumor  cells promote  thrombosis.  The attachment of 
malignant cells can promote thrombosis by activating local-
ized clotting factor, favoring platelet aggregation and activat-
ing leukocytes which then release their cytokines [8, 10, 29, 
40]. 
  It  has  also  been  shown  that  inflammation  induced  by 
cancer can increase acute-phase proteins including fibrino-
gen,  coagulation  factor  VIII  and  von  Willebrand  factor, 
which  can  promote  thrombosis  [9,  41].  Fig.  (1)  illustrates  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Factors involved in cancer-associated thrombosis. 
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the mechanism of thrombosis formation induced by cancer 
cells. 
EPIDEMIOLOGY  OF  CANCER-ASSOCIATED 
THROMBOSIS 
  It is estimated that about 4-20% of patients with cancer 
experience venous thrombosis [7, 10, 25, 30, 42, 43] with the 
annual  incidence  of  0.5%  in  cancer  patients  compared  to 
0.1% in the general population [25]. In patients with cancer, 
the risk of VTE is estimated to be 4-fold to 7-fold higher 
than  in  patients  without  cancer  [44].  Venous  thromboem-
bolism  and  thrombotic  complications  are  the  second  most 
frequent cause of mortality in patients with cancer [10].  
  Several studies have showed that the incidence of VTE is 
associated with the duration of the underlying illness. The 
highest rate of VTE is seen in the initial period after diagno-
sis [14, 29, 45] and mortality from VTE is highest 1 year 
after diagnosis [14]. Alcalay et al. showed that the incidence 
of VTE in patients with colorectal cancer is about 5.0% dur-
ing the first 6 months after diagnosis, 1.4% during the subse-
quent 7-12 months and 0.6% 13-24 months after diagnosis 
[46]. The appearance of venous thrombosis has been clearly 
associated with metastatic cancer and the stage of cancer [14, 
29, 42, 44]. About 10% of patients with idiopathic throm-
botic complications are diagnosed with malignancy within a 
few years after thrombotic events and approximately 40% of 
them have metastatic cancer at diagnosis [47, 48]. As a result 
VTE  is  sometimes  the first manifestation of occult cancer 
[10, 29, 42, 47]. In a study by Monreal et al. the rate of oc-
cult cancer in patients with idiopathic VTE was 2.2%-12% 
[48]. More advanced stages of cancer on initial diagnosis are 
also related with a higher incidence of VTE [14, 45, 46].  
  The  presence  of  medical  comorbodity  has  an  adverse 
effect on prognosis and survival in patients with cancer who 
also have thrombosis [47]. Khorana et al. proposed a simple 
risk  scoring  system  based  on  clinical  and  laboratory  vari-
ables  to  predict  chemotherapy-associated  VTE  in  patients 
with cancer [25, 49]. They identified five variables based on 
the site of cancer, pre-chemotherapy platelet and leukocyte 
count, hemoglobin level and body mass index. This model 
predicts a risk of chemotherapy-associated VTE in of about 
7% in patients with cancer [25]. 
PREVENTION  AND  TREATMENT  OF  VENOUS 
THROMBOEMBOLISM IN CANCER 
  Effective prophylaxis and treatment of VTE can reduce 
morbidity and mortality due to thrombosis. Low-molecular-
weight-heparin (LMWH) is the first choice for prophylaxis 
and treatment of acute VTE, having largely replaced unfrac-
tionated  heparin  and  oral  vitamin  K  antagonists  such  as  
warfarin [50, 51]. 
  Warfarin is a long-term anticoagulant for the prevention 
and treatment of VTE that is given after initial therapy with 
unfractionated  heparin  or  LMWH  to  maintain  an  interna-
tional normalized ratio of 2-3 [42, 52]. But warfarin treat-
ment in patients with cancer has several problems that have 
limited its use. Long-term treatment with warfarin increases 
the  risk  of  bleeding  and  recurrent  VTE  in  patients  with  
cancer [47, 53, 54]. Difficulties in dose adjustment also limit 
its use because the anticoagulant effect may reach to its peak 
after 3-4 days and its clearance from plasma is slow. Also 
warfarin  may  interact  with  chemotherapeutic  agents  and 
foods—interactions  that  also  make  this  drug  difficult  to 
manage [12]. 
  The CLOT trial (Comparison of Low-Molecular-Weight 
Heparin Versus Oral Anticoagulant Therapy for the Preven-
tion of Recurrent Venous Thromboembolism in Patients with 
Cancer)  compared  the  efficacy  of  LMWH  plus  dalteparin 
and  oral  warfarin  in  preventing  recurrent  VTE  in  patients 
with cancer. Recurrent VTE was found in 27 of 336 patients 
in  the  LMWH  group  compared  to  53  of  336  patients  in  
the  warfarin  group  (hazard  ratio  0.48,  P=0.002)  [55].  
Low-molecular-weight  heparin  and  dalteparin  reduced  the 
risk of recurrent VTE by 52% compared to warfarin therapy 
[56]. 
  Unfractionated heparin is also widely used for the treat-
ment  and  prophylaxis  of  thrombophylactic  events  and  its 
efficacy is similar to that of LMWH [56]. A metaanalysis 
revealed that unfractionated heparin decreased the incidence 
of deep vein thrombosis and pulmonary embolism by 56% 
and 58% respectively compared to  the control group [57]. 
The most important limitation of unfractionated heparin is 
the appearance of heparin-induced thrombocytopenia, which 
is significantly less frequent with LMWH [9, 29]. Treatment 
with LMWH led to a significant proportion of improvements 
in thrombosis and higher survival compared to unfraction-
ated  heparin  [9].  These  benefits  make  subcutaneous  (sc) 
LMWH the first-line choice for the treatment and prophy-
laxis of thrombosis in patients with cancer. 
  Randomized trials to test different types of prophylaxis 
for VTE in patients with cancer showed significantly lower 
rates of VTE with LMWH compared to unfractionated hepa-
rin or a placebo [58-60]. New treatment guidelines from the 
National  Comprehensive  Cancer  Network  (NCCN)  and 
American  Society  of  Clinical  Oncology  (ASCO)  accept  
prophylaxis for VTE in hospitalized cancer patients in the 
absence of major bleeding or other contraindications to anti-
coagulants  [50,  61].  Contraindications  to  anticoagulation 
according to ASCO guidelines include uncontrollable bleed-
ing, active cerebrovascular hemorrhage, dissecting or cere-
bral aneurysm, bacterial endocarditis, active peptic or other 
gastrointestinal ulceration, severe uncontrolled or malignant 
hypertension,  severe  head  trauma,  pregnancy  (warfarin), 
heparin-induced  thrombocytopenia  and  epidural  catheter 
placement.  
  It  is  recommended  that  patients  undergoing  major  
surgery  for  cancer  should  be  considered  candidates  for 
thrombophylaxis,  although  routine  prophylaxis  is  not  
recommended  in  ambulatory  cancer  patients  without  VTE 
except  in  patients  with  myeloma  receiving  thalidomide  or 
lenalidomide treatment [50]. Low-molecular-weight heparin, 
dalteparin 5000 units s.c daily, enoxaparin 40 mg s.c daily or 
fondaparinux 2.5 mg s.c daily is recommended for prophy-
laxis of VTE in patients with cancer [50, 61, 62]. A random-
ized clinical trial of combination chemotherapy with LMWH 
with dalteparin 5000 units once daily for 18 weeks compared 
to  chemotherapy  alone  in  patients  with  small-cell  lung  
cancer  revealed  that  combination  therapy  with  dalteparin 
increased  disease-free  survival  (10  months)  compared  
chemotherapy alone (6 months, P=0.01) [63]. Cancer-Associated Thrombosis  The Open Cardiovascular Medicine Journal, 2010, Volume 4    81 
CONCLUSIONS 
  Venous  thromboembolism  is  a  serious  complication  
and the second most frequent cause of death in patients with 
cancer. The appearance of VTE reduces survival in cancer 
patients  compared  to  those  without  VTE  and  adversely  
affects quality of life [14]. It is estimated that thrombosis in 
patients with cancer increases the risk of death 4-fold to 8-
fold  compared  to  patients  without  cancer  [47].  Landmark 
studies showed that anticoagulant therapy and thrombopro-
phylaxis are efficacious and can protect patients from VTE. 
Based  on  clinical  trial  findings,  subcutaneous  LMWH  is  
the first line therapy for VTE  in patients with  cancer  and  
has largely replaced unfractionated heparin  and vitamin  K  
antagonists. New  treatment  and prophylaxis guidelines are 
now available for the management of thrombotic events and 
these guidelines can decrease complications  and morbidity 
and  increase  survival  and  quality  of  life  in  patients  with  
cancer.  
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CP  =  Cancer procoagulant 
TF  =  Tissue factor 
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FVIII  =  Factor VIII 
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